Iqvia Holdings Inc (NYSE:IQV) was the recipient of a significant growth in short interest in June. As of June 30th, there was short interest totalling 2,704,000 shares, a growth of 6.4% from the May 30th total of 2,541,500 shares. Based on an average trading volume of 1,320,000 shares, the days-to-cover ratio is presently 2.0 days. Approximately 1.5% of the shares of the company are sold short.

Several equities analysts have recently weighed in on IQV shares. William Blair reissued an “outperform” rating on shares of Iqvia in a research report on Wednesday, June 19th. Zacks Investment Research lowered shares of Inflarx from a “buy” rating to a “hold” rating in a research report on Friday, May 3rd. Stifel Nicolaus set a $14.00 price objective on shares of Oasis Petroleum and gave the company a “buy” rating in a research report on Wednesday, June 19th. Mizuho set a $21.00 price objective on shares of Neon Therapeutics and gave the company a “buy” rating in a research report on Friday, June 21st. Finally, Leerink Swann started coverage on shares of Alder Biopharmaceuticals in a research report on Tuesday, May 28th. They issued an “outperform” rating and a $21.00 price objective on the stock. Three equities research analysts have rated the stock with a hold rating, seventeen have given a buy rating and two have assigned a strong buy rating to the stock. Iqvia presently has an average rating of “Buy” and an average target price of $155.49.

NYSE:IQV opened at $156.57 on Wednesday. Iqvia has a 52 week low of $104.90 and a 52 week high of $164.13. The company has a market capitalization of $31.20 billion, a price-to-earnings ratio of 30.58, a price-to-earnings-growth ratio of 1.91 and a beta of 0.87. The business’s 50-day simple moving average is $149.70. The company has a current ratio of 1.14, a quick ratio of 1.14 and a debt-to-equity ratio of 1.69.

Iqvia (NYSE:IQV) last released its quarterly earnings results on Wednesday, May 1st. The medical research company reported $1.53 EPS for the quarter, topping analysts’ consensus estimates of $1.41 by $0.12. Iqvia had a net margin of 2.35% and a return on equity of 15.08%. The business had revenue of $2.68 billion for the quarter, compared to analyst estimates of $2.67 billion. During the same period last year, the firm earned $1.34 earnings per share. Iqvia’s revenue for the quarter was up 4.7% compared to the same quarter last year. As a group, analysts anticipate that Iqvia will post 5.89 EPS for the current fiscal year.

In other Iqvia news, insider Ari Bousbib sold 96,000 shares of the company’s stock in a transaction on Wednesday, June 19th. The shares were sold at an average price of $150.00, for a total transaction of $14,400,000.00. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Kevin C. Knightly sold 46,080 shares of the company’s stock in a transaction on Friday, May 3rd. The stock was sold at an average price of $138.06, for a total transaction of $6,361,804.80. The disclosure for this sale can be found here. Insiders have sold 238,080 shares of company stock worth $36,121,805 over the last ninety days. Insiders own 6.00% of the company’s stock.

Institutional investors have recently made changes to their positions in the business. C J Advisory Inc acquired a new stake in Iqvia during the first quarter worth about $27,000. Baystate Wealth Management LLC acquired a new stake in Iqvia during the first quarter worth about $27,000. Parkside Financial Bank & Trust grew its stake in Iqvia by 140.2% during the first quarter. Parkside Financial Bank & Trust now owns 209 shares of the medical research company’s stock worth $30,000 after buying an additional 122 shares in the last quarter. Cornerstone Advisors Inc. grew its stake in Iqvia by 47.2% during the second quarter. Cornerstone Advisors Inc. now owns 399 shares of the medical research company’s stock worth $64,000 after buying an additional 128 shares in the last quarter. Finally, Kaizen Advisory LLC grew its stake in Iqvia by 33.1% during the fourth quarter. Kaizen Advisory LLC now owns 450 shares of the medical research company’s stock worth $52,000 after buying an additional 112 shares in the last quarter. Hedge funds and other institutional investors own 89.69% of the company’s stock.

About Iqvia

IQVIA Holdings Inc provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Featured Story: Technical Analysis

Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.